Back to Agenda
Convergence in Regulatory Science Across the Strait
Session Chair(s)
Ning Li, MD, PhD
Vice President, Head of Asia Regulatory and Medical Policy
Sanofi, China
In this forum, representatives from the Center of Drug Evaluation from mainland China and the Center for Drug Evaluation from Taiwan will share their views and experience in Good Review Practice (GRP) and IND review. This will form the basis for the discussion of collaboration opportunities and areas of convergence in regulatory science in the two centers.
Learning Objective : Discuss the framework and experience in GRP (good review practices); Identify the principles and practice in IND review.
Speaker(s)
Moderator
Ling Su, PhD
Shenyang Pharmaceutical University, Yeehong Business School, China
Research Fellow
Point of View from China CDE
Yi Feng
Fountain Medical Development Ltd., China
SVP, Medical and Reg Affairs
IND Review: Point of View from China CDE
Zhen Chen, PhD
Center for Drug Evaluation of CFDA , China
Deputy Office Director, Office of New Drug Pharmaceutical Science
Point of View from Taiwan CDE
Hsin-Jung Lee
Center for Drug Evaluation , Taiwan
Reviewer, Division of New Drugs
Point of View from Taiwan CDE
Mey Wang, PhD
Center for Drug Evaluation, Taiwan
Reviewer, Division of New Drugs
Have an account?